TrumpRx: Trump Scores Significantly Lower Prices For Popular Weight Loss Drugs

President Donald Trump announced on Thursday that he’s reached deals with major pharmaceutical companies to lower the costs of popular weight loss drugs known as GLP-1s.

Pharma companies Eli Lilly, which makes Zepbound, and Novo Nordisk, which makes Wegovy and Ozempic, have agreed to lower prices of their drugs to the tune of hundreds of dollars, Trump said. Notably, Ozempic is primarily a type 2 diabetes medication, but is often prescribed off-label for weight loss.

Now, monthly out-of-pocket costs of the drugs will range from $50 to around $350, depending on a person’s dosage and insurance coverage. The drugs currently cost at least $1,000 a month.

Medicare patients will cover a $50 copay each month for the injectable drugs, no matter if the medications are used for obesity or diabetes.

Through Trump’s direct-to-consumer government website, called TrumpRx, Americans will pay $350-a-month for Wegovy, Zepbound, or Ozempic. Moreover, the cost is expected to soon drop to $245 a month, according to the administration.

???????? President Trump announces another HISTORIC PRICE SLASH on top drugs that help Americans struggling with diabetes, heart disease, obesity, and more.

????Ozempic: $1,000 → $350/mo via TrumpRx
????Wegovy: $1,350 → $350/mo

MAKE AMERICA HEALTHY AGAIN! pic.twitter.com/9lezvtZ6q0

— The White House (@WhiteHouse) November 6, 2025

Additionally, both Eli Lilly and Novo Nordisk are working on oral GLP-1 medications for the public. The companies plan to make those available on TrumpRx for $150 per month, the White House said.

???? BREAKING: @POTUS announces that pharmaceutical companies Eli Lilly and Novo Nordisk have agreed to offer their most popular GLP-1 drugs “at drastic discounts.” pic.twitter.com/PG9ffacUJf

— Rapid Response 47 (@RapidResponse47) November 6, 2025

Health and Human Services Secretary Robert F. Kennedy Jr. praised the deal.

“This is the biggest drug in our country, and that’s why this is the most important of all the announcements we’ve made,” he said. “This is going to have the biggest impact on the American people. All Americans, even those who are not on Medicaid, Medicare, are going to be able to get the same price for their drugs, for their GLP-1s.”

“The American public, because of this agreement, will lose 125 million pounds by this time next year — so it is going to have dramatic effects on human health in this country,” RFK added.

.@SecKennedy: “The American public, because of this agreement, will lose 125 million pounds by this time next year — so it is going to have dramatic effects on human health in this country.” https://t.co/Wq2nrKUdUG pic.twitter.com/GTKc0vjfdi

— Rapid Response 47 (@RapidResponse47) November 6, 2025

Eli Lilly will also provide Emgality, a treatment for migraines, for $299 per pen, which is $443 lower than the current list price. Also, a diabetes medicine from Eli Lilly called Trulicity will be discounted by $598, now costing $389 per month.

NovoLog and Tresiba, popular insulin products from Novo Nordisk, will now cost $35 per month.

The president has also secured a $10 billion investment from Novo Nordisk to “to strengthen its domestic footprint” in the U.S. and $27 billion from Eli Lilly in new U.S. manufacturing investments.